

# VBC Release Highlights

June 30, 2023

Practice Insights<sup>SM</sup> is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

## MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect the following new measures:

- PIMSH 15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
  - Percentage of cancer patients aged 18 years and older treated with low- or minimal-emetic-risk antineoplastic agents in the infusion center who are administered inappropriate pre-treatment antiemetic therapy
- PIMSH 16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center
  - Percentage of cancer patients aged 18 years and older treated with high- or moderate-emetic-risk antineoplastic agents in the infusion center who are administered appropriate pre-treatment antiemetic therapy.

## Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

**NOTE:** Table continues on the next page.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#450	Trastuzumab Received by Patients with AJCC Stage (T1c), II, and III and HER2+ Breast Cancer Receiving Adj Chemo
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement

Measure	Description
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center